Table 2.
Characteristics and Outcomes of Personalized Trials of Blood Pressure Medications
| Patient | Treatment prior to trial | Treatment sequence | Percent of days monitored, with side effects | Treatment preference at the end of trial | Prescribed > 6 weeks after trial | Helpfulness of participation | Recommend trial to others |
|---|---|---|---|---|---|---|---|
| A | HCTZ-bisoprolol | HB-A1-Lo-Lo-A2-HB-M | HB = 0% (0 of 14) | HCTZ-bisoprolol | HCTZ-bisoprolol | Extremely helpful | Yes |
| A1 = 0% (0 of 3) | |||||||
| Lo = 0% (0 of 14) | |||||||
| A2 = 0% (0 of 7) | |||||||
| M = 0% (0 of 1) | |||||||
| B | Lisinopril | Lo-A-H | Lo = 0% (0 of 7) | No preference | Lisinopril | Somewhat helpful | Yes |
| A = 29% (2 of 7) | |||||||
| H = 20% (1 of 5) | |||||||
| C | Amlodipine | Lo-A-H | Lo = 25% (1 of 4) | Losartan | Losartan | Very helpful | Yes |
| A = n/a* | |||||||
| H = n/a | |||||||
| D | None | Lo-A-H-H-A-Lo-A-Lo-H | Lo = 0% (0 of 17) | HCTZ | HCTZ | Extremely helpful | Yes |
| A = 0% (0 of 19) | |||||||
| H = 0% (0 of 17) | |||||||
| E | Lisinopril | Lo-Li-H | Lo = 0% (0 of 6) | Lisinopril | Lisinopril | Not at all helpful | Yes |
| Li = 0% (0 of 4) | |||||||
| H = 0% (0 of 7) | |||||||
| F | HCTZ-triamterene | HT-Lo-A-A-Lo-HT | HT = 0% (0 of 13) | HCTZ-triamterene | HCTZ-triamterene | Very helpful | Yes |
| Lo = 0% (0 of 11) | |||||||
| A = 9% (1 of 11) | |||||||
| G | Chlorthalidone | C-H | C = 0% (0 of 6) | Chlorthalidone | Chlorthalidone | Extremely helpful | Yes |
| H = 0% (0 of 7) |
A amlodipine, A1 low-dose amlodipine, A2 medium-dose amlodipine, C chlorthalidone, H hydrochlorothiazide, HB hydrochlorothiazide-bisoprolol, HT hydrochlorothiazide-triamterene, Lo losartan, Li Lisinopril, M metoprolol, n/a data not provided, SBP systolic blood pressure
*Participant self-reported prominent leg edema while taking amlodipine but did not complete self-assessments electronically